Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evaluation and modelling of the performance of an automated SARS-CoV-2 antigen assay according to sample type, target population and epidemic trends

View ORCID ProfileNicolas Yin, Cyril Debuysschere, Valery Daubie, Marc Hildebrand, Charlotte Martin, Sonja Curac, Fanny Ponthieux, Marie-Christine Payen, Olivier Vandenberg, Marie Hallin
doi: https://doi.org/10.1101/2022.01.14.22269064
Nicolas Yin
1Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles – Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicolas Yin
  • For correspondence: nicolas.yin@lhub-ulb.be
Cyril Debuysschere
1Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles – Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valery Daubie
1Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles – Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Hildebrand
2Department of Internal Medicine, Erasme University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte Martin
3Department of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonja Curac
4Emergency Department, Erasme University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fanny Ponthieux
1Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles – Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Christine Payen
3Department of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Vandenberg
5Centre for Environmental Health and Occupational Health, School of Public Health, Université Libre de Bruxelles (ULB), Brussels, Belgium
6Clinical Research and Innovation Unit, Laboratoire Hospitalier Universitaire de Bruxelles – Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels, Belgium
7Division of Infection and Immunity, Faculty of Medical Sciences, University College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Hallin
1Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles – Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels, Belgium
5Centre for Environmental Health and Occupational Health, School of Public Health, Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The Lumipulse® G SARS-CoV-2 Ag assay performance was evaluated on prospectively collected saliva and nasopharyngeal swabs (NPS) of recently ill in- and outpatients and according to the estimated viral load. Performances were calculated using RT-PCR positive NPS from patients with symptoms ≤ 7 days and RT-PCR negative NPS as gold standard. In addition, non-selected positive NPS were analyzed to assess the performances on various viral loads. This assay yielded a sensitivity of 93.1% on NPS and 71.4% on saliva for recently ill patients. For NPS with a viral load > 103 RNA copies/mL, sensitivity was 96.4%. A model established on our daily routine showed fluctuations of the performances depending on the epidemic trends but an overall good negative predictive value. Lumipulse® G SARS-CoV-2 assay yielded good performance for an automated antigen detection assay on NPS. Using it for the detection of recently ill patient or to screen high-risk patients could be an interesting alternative to the more expensive RT-PCR.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was funded by Fujirebio. The authors did not perceive any personal grants or funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Erasme university hospital ethics' committee approved and reviewed the comparative performance evaluation study on saliva and nasopharyngeal swabs. Ethics' comittee of Saint-Pierre hospital waived ethical approval for the use of residual human body material for evaluation purpose.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the supplementary material.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 14, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation and modelling of the performance of an automated SARS-CoV-2 antigen assay according to sample type, target population and epidemic trends
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluation and modelling of the performance of an automated SARS-CoV-2 antigen assay according to sample type, target population and epidemic trends
Nicolas Yin, Cyril Debuysschere, Valery Daubie, Marc Hildebrand, Charlotte Martin, Sonja Curac, Fanny Ponthieux, Marie-Christine Payen, Olivier Vandenberg, Marie Hallin
medRxiv 2022.01.14.22269064; doi: https://doi.org/10.1101/2022.01.14.22269064
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Evaluation and modelling of the performance of an automated SARS-CoV-2 antigen assay according to sample type, target population and epidemic trends
Nicolas Yin, Cyril Debuysschere, Valery Daubie, Marc Hildebrand, Charlotte Martin, Sonja Curac, Fanny Ponthieux, Marie-Christine Payen, Olivier Vandenberg, Marie Hallin
medRxiv 2022.01.14.22269064; doi: https://doi.org/10.1101/2022.01.14.22269064

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (860)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (250)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8562)
  • Forensic Medicine (4)
  • Gastroenterology (384)
  • Genetic and Genomic Medicine (1753)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1244)
  • Health Policy (621)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (374)
  • Infectious Diseases (except HIV/AIDS) (10303)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (212)
  • Neurology (1678)
  • Nursing (97)
  • Nutrition (251)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (451)
  • Oncology (929)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (536)
  • Pharmacology and Therapeutics (253)
  • Primary Care Research (208)
  • Psychiatry and Clinical Psychology (1770)
  • Public and Global Health (3841)
  • Radiology and Imaging (624)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (520)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)